PT  - JOURNAL ARTICLE
AU  - Hunter, Stephanie R.
AU  - Hannum, Mackenzie E.
AU  - Pellegrino, Robert
AU  - O’Leary, Maureen A.
AU  - Rawson, Nancy E.
AU  - Reed, Danielle R.
AU  - Dalton, Pamela H.
AU  - Parma, Valentina
TI  - Proof-of-concept: SCENTinel 1.1 rapidly discriminates COVID-19 related olfactory disorders
AID  - 10.1101/2022.03.23.22272807
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.23.22272807
4099  - http://medrxiv.org/content/early/2022/11/08/2022.03.23.22272807.short
4100  - http://medrxiv.org/content/early/2022/11/08/2022.03.23.22272807.full
AB  - It is estimated that 20-67% of those with COVID-19 develop olfactory disorders, depending on the SARS-CoV-2 variant. However, there is an absence of quick, population-wide olfactory tests to screen for olfactory disorders. The purpose of this study was to provide a proof-of-concept that SCENTinel 1.1, a rapid, inexpensive, population-wide olfactory test, can discriminate between anosmia (total smell loss), hyposmia (reduced sense of smell), parosmia (distorted odor perception), and phantosmia (odor sensation without a source). Participants were mailed a SCENTinel 1.1 test, which measures odor detection, intensity, identification, and pleasantness, using one of four possible odors. Those who completed the test (N = 381) were divided into groups based on their self-reported olfactory function: quantitative olfactory disorder (anosmia or hyposmia, N = 135), qualitative olfactory disorder (parosmia and/or phantosmia; N = 86), and normosmia (normal sense of smell; N = 66). SCENTinel 1.1 accurately discriminates quantitative olfactory disorders, qualitative olfactory disorders, and normosmia groups. When olfactory disorders were assessed individually, SCENTinel 1.1 discriminates between hyposmia, parosmia and anosmia. Participants with parosmia rated common odors less pleasant than those without parosmia. We provide proof-of-concept that SCENTinel 1.1, a rapid smell test, can discriminate quantitative and qualitative olfactory disorders, and is the only direct test to rapidly discriminate parosmia.Competing Interest StatementOn behalf of the authors of this manuscript the Monell Chemical Senses Center and Temple University have been awarded patent protection (US patent no 11 337 640) and this patent has been licensed to Ahersla Health Inc. The authors may benefit financially through their institution's patent policy.Funding StatementWe acknowledge support from the National Institutes of Health as part of the RADx-rad initiative (U01 DC019578 to PHD and VP). MEH was supported by NIH T32 (DC000014) and F32 (DC020100) funding during this work; RP was supported by NIH T32 funding (DC000014) and F32 (DC020380).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of Pennsylvania Institutional Review Board (protocol no. 844425) and complied with the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data and analysis script will be publicly available on OSF upon peer-reviewed publication (48). https://osf.io/5d7kx/